Updates
Jan. 1, 2012
Lipitor’s Patent Ends, Pfizer Squares Off with Generics
Lipitor, the best-selling drug in history lost its patent in late November, leaving the market open to generic rivals.
Lipitor, the best-selling drug in history lost its patent in late November, leaving the market open to generic rivals, which could grab all its market share in no time. But Pfizer, the makers of the blockbuster cholesterol prescription drug, isn't throwing in the towel, for good reason, Lipitor brings in nearly $11 billion a year.
In anticipation of the end of Lipitor's patent, Pfizer began promoting discounts and incentives for patients and insurers to make the brand-name dr...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In